Abstract
A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antibodies, Monoclonal* / administration & dosage
-
Antibodies, Monoclonal* / immunology
-
Antibodies, Monoclonal* / therapeutic use
-
Antibodies, Viral* / administration & dosage
-
Antibodies, Viral* / immunology
-
Antibodies, Viral* / therapeutic use
-
Disease Models, Animal
-
Ebolavirus / immunology*
-
Ebolavirus / pathogenicity
-
Guinea Pigs
-
Hemorrhagic Fever, Ebola / immunology
-
Hemorrhagic Fever, Ebola / prevention & control*
-
Hemorrhagic Fever, Ebola / therapy
-
Humans
-
Immunization, Passive*
-
Neutralization Tests
Substances
-
Antibodies, Monoclonal
-
Antibodies, Viral